某院肺癌治疗药物临床使用情况分析
投稿时间:2023-12-29  修订日期:2024-05-11  点此下载全文
引用本文:
摘要点击次数: 164
全文下载次数: 0
作者单位邮编
刘爽 河北北方学院 075061
吴燕秋 北京大学人民医院 
易洪彬 沈阳药科大学 
蒯丽萍 中国药学会科技开发中心 
徐冬艳 中国药学会科技开发中心 
汤建华 河北北方学院附属第一医院 
中文摘要:目的 比较和分析肺癌治疗药物在国家启动医保谈判前后的使用变化情况,研究一系列政策对肺癌用药的影响。方法 运用描述性统计方法,分析北京大学人民医院2014-2020年肺癌患者的基本情况和相应治疗药物的变化情况,并结合全国医药信息网中肺癌治疗药物医院采购数据进行分析。结果 2014-2020年肺癌患者人均总费用整体呈现先上升后下降趋势,在国家药品医保谈判前不断增长,谈判后逐步降低。在2017年之后,VEGF/VEGFR抑制剂和EGFR酪氨酸激酶抑制剂等ATC小类用量明显增加,单克隆抗体品种数也在增多。奥希替尼、安罗替尼、阿来替尼、克唑替尼等医保目录药品的DDDs上升趋势明显,日均费用明显降低。结论 近年来,肺癌患者住院天数持续缩短,用药结构发生显著变化。国家医保目录的调整使更多的肺癌创新药呈现“量升价降”趋势。
中文关键词:肺癌  使用频度  用药金额  日均费用
 
Analysis of clinical use of drugs for lung cancer treatment in a hospital
Abstract:Objective To compare and analyze the changes in the use of lung cancer therapeutic drugs before and after the national initiation of health insurance negotiations, and to study the impact of a series of policies on the use of lung cancer drugs. Methods Descriptive statistical methods were used to analyze the basic situation of lung cancer patients and the changes of corresponding therapeutic drugs in Peking University People's Hospital from 2014 to 2020, as well as to analyze the hospital procurement data of lung cancer therapeutic drugs in the database of the Chinese Medicine Economic Information. Results From 2014 to 2020, the total cost per capita of lung cancer patients showed a trend of first increasing and then decreasing, increasing before the national drug negotiation and gradually decreasing after the negotiation. After 2017, the use of small ATC classes such as VEGF/VEGFR inhibitors and EGFR tyrosine kinase inhibitors increased significantly, along with a rise in the number of monoclonal antibody varieties. The DDDs of osimertinib, anlotinib, alectinib, crizotinib and other drugs in the medical insurance list increased significantly, and the average daily cost decreased significantly. Conclusion The number of hospitalization days for lung cancer patients has continued to shorten in recent years, and the structure of drug use has changed significantly. The adjustment of the medical insurance catalog has led to more innovative lung cancer drugs showing the trend of "volume up and price down".
keywords:Lung cancer  Defined daily doses  Medication Cost  Defined daily dose cost
  查看/发表评论  下载PDF阅读器
关闭

分享按钮